Can sound waves clear up skin? new trial tests ultrasound for pigment and rosacea

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants aged 20 to 60 years. 2. Diagnosed by the investigator as having facial pigmentary disease or rosacea eligible for this study. 3. Participants with rosacea must meet the diagnostic criteria of the Chinese Guideline for the Diagnosis and Treatment of Rosacea (2021 edition). 4. Participants with facial pigmentary diseases must be diagnosed by two dermatologists with associate senior professional title or above, based on clinical manifestations and, when necessary, auxiliary examinations such as Wood's lamp examination, dermoscopy, or skin histopathology. Eligible pigmentary diseases may include melasma, periorbital hyperpigmentation, melanosis, lichen planus pigmentosus, or other facial pigmentary diseases considered suitable for this study. 5. The skin lesions are suitable for microfocused ultrasound treatment and follow-up assessment. 6. Able to comply with study treatment, follow-up visits, photography, and related assessments during the study. 7. Able to understand the study procedures, voluntarily participate in the study, and sign written informed consent. Exclusion Criteria: 1. Pregnant or lactating women, or women planning to become pregnant during the study period. 2. Known allergy to ultrasound coupling gel or any of its excipients. 3. Presence of other obvious active inflammatory skin diseases, infectious skin diseases, or other facial skin conditions that may affect efficacy evaluation, apart from the target disease of this study. 4. Use within 1 month before screening of topical medications or procedures that may affect study evaluation, including but not limited to corticosteroids, calcineurin inhibitors, depigmenting agents, or energy-based treatments. 5. Severe cardiac, hepatic, renal, or other important organ dysfunction, or other severe systemic diseases that, in the investigator's judgment, may affect the safety or efficacy evaluation of this study. 6. Participation in another clinical trial within 30 days before screening. 7. History of prolonged intense sun exposure within 1 month before screening, or expected inability to avoid significant sun exposure or outdoor exposure during the study period, which may affect study evaluation. 8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.